AXSM: Axsome Therapeutics, Inc. Stock

by  •  • Comments Off on AXSM: Axsome Therapeutics, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 5,307.19
Enterprise Value ($M) 5,187.65
Book Value ($M) 53.20
Book Value / Share 1.08
Price / Book 99.75
NCAV ($M) -48.83
NCAV / Share -0.99
Price / NCAV -108.68

Profitability (mra)
Return on Invested Capital (ROIC) -1.06
Return on Assets (ROA) -0.51
Return on Equity (ROE) -1.93

Liquidity (mrq)
Quick Ratio 1.96
Current Ratio 2.03

Balance Sheet (mrq) ($M)
Current Assets 494.63
Assets 596.67
Liabilities 543.47
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 385.69
Operating Income -252.44
Net Income -287.22
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -128.41
Cash from Investing -0.27
Cash from Financing 57.84

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Rtw Investments, Lp 8.40 -9.76

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO
2025-02-18 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 ☐ TRANSITION REPORT PURSUANT
2024-08-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO S

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 81,913 349,491 23.44
2025-05-08 106,540 501,362 21.25
2025-05-07 172,076 535,877 32.11
2025-05-06 235,259 646,496 36.39
2025-05-05 263,892 860,595 30.66

(click for more detail)

Similar Companies
AURA – Aura Biosciences, Inc. AVBP – ArriVent BioPharma, Inc.
AVDL – Avadel Pharmaceuticals plc BCAB – BioAtla, Inc.
BHST – BioHarvest Sciences Inc.


Financial data and stock pages provided by
Fintel.io

Finpedia: Axsome Therapeutics